title: Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.
abstract: The aim of this retrospective study was to evaluate the objective clinical response (cOR), pathological complete response (pCR), and progression-free survival (PFS) in 231 Russian patients with four subtypes of breast cancer treated with neoadjuvant chemotherapy. About 130 (56.3 %) patients received anthracycline-based, 56 (24.2 %) capecitabine-containing (CAX), 28 (12.1 %) taxotere and 17 (7.4 %) non-anthracycline-containing chemotherapy regimens at the Tomsk Cancer Research Institute between 2000 and 2010. Tumors were subtyped according to the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) immunohistochemical data. The majority of tumors (48.9 %) were ER+/PR+ and HER2-negative (HR+/HER2-), 10.4 % were ER+ PR+ and HER2-positive (HR+/HER2+), 9.1 % were ER-/PR- and HER2-overexpressed (HER2-enriched) and 31.6 % were ER-/PR- and HER2-negative (triple negative). Both cOR and pCR were significantly higher in the triple-negative tumors compared to the other subtypes (P = 0.021 and P = 0.033, respectively). Among the four chemotherapy regimens, only CAX regimen had a predictive value for cOR (HR 2.30, 95 % CI 1.16-4.58, P = 0.009). Multivariate regression analysis showed that the triple-negative subtype (HR 2.54, 95 % CI 1.06-1.42, P = 0.011) and CAX regimen (HR 3.01, 95 % CI 1.01-1.46, P = 0.002) were significantly associated with cOR. No association between patient's PFS and a tumor subtype was observed. However, there was a trend for a prolonged PFS among patients with cOR (P = 0.056). Our data indicate a potentially better prognosis for triple-negative breast cancer patients if treated with the CAX neoadjuvant regimen.
authors.affiliation: Department of Molecular Oncology and Immunology, Cancer Research Institute of Siberian Branch, Russian Academy of Medical Sciences, 5 Kooperativny Street, Tomsk, 634050, Russian, nbabyshkina@mail.ru.
authors.forename: Nataliya
authors.initials: N
authors.lastname: Babyshkina
authors.forename: Elena
authors.initials: E
authors.lastname: Malinovskaya
authors.forename: Stanislav
authors.initials: S
authors.lastname: Patalyak
authors.forename: Olga
authors.initials: O
authors.lastname: Bragina
authors.forename: Natalia
authors.initials: N
authors.lastname: Tarabanovskaya
authors.forename: Artem
authors.initials: A
authors.lastname: Doroshenko
authors.forename: Elena
authors.initials: E
authors.lastname: Slonimskaya
authors.forename: Vladimir
authors.initials: V
authors.lastname: Perelmuter
authors.forename: Nadejda
authors.initials: N
authors.lastname: Cherdyntseva
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000706:statistics & numerical data*; D011379:Prognosis; D012189:Retrospective Studies; D012426:Russia / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents